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Type 2 diabetes is a progressive disorder associated
with declining pancreatic beta cell function and
increasing insulin resistance. This often results in the
need for combination therapies in order to maintain
target HbA1C by escalating drug treatment from
monotherapy (usually with metformin) to combina-
tion therapies on a platform of healthy lifestyle and
weight control.
All patients should receive education about their
disorder and be encouraged to adopt a healthy life-
style and lose excess weight but, despite the contin-
uing need for a healthy lifestyle, most require drug
treatment. The UKPDS study showed that only 25%
of newly diagnosed patients could maintain target
HbA1C after 3 years using diet alone; this declined to
9% after 9 years (1). The aim is to maintain target
HbA1C as beta cell function declines by escalating
drug treatment from monotherapy (usually with
metformin) to combined treatment (usually with a
sulfonylurea).
From the recent NICE guidance, if glycaemic con-
trol remains inadequate, the next step is to add treat-
ment with insulin, a glitazone or exenatide, the
choice depending on both clinical factors and patient
preference. Many patients with type 2 diabetes
require insulin to maintain glycaemic control. In UK
general practice, it is estimated that only half of
patients who need insulin after failure of oral agents
will receive it within 5 years (2). The median time
from beginning treatment with the last oral agent to
beginning insulin therapy is approximately 8 years
(3).
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Summary
Guidance has been published on the choice of initial insulin regimen for patients
with type 2 diabetes [NPH (isophane) insulin or a long-acting insulin analogue] but
not on how to choose a second regimen when glycaemic control becomes unsatis-
factory. Aims: To develop pragmatic clinical guidance for choosing a second-line
insulin regimen tailored to the individual needs of patients with type 2 diabetes
after failure of ﬁrst-line insulin therapy. Methods: Formulation of a consensus by
expert panel based on published evidence and best clinical practice, taking into
account patient preferences, lifestyle and functional capacity. Results: Six patient-
dependent factors relevant to the choice of second-line insulin regimen and three
alternative insulin regimens (twice-daily premixed, basal-plus and basal-bolus) were
identiﬁed. The panel recommended one or more insulin regimens compatible with
each factor, emphasising the fundamental importance of a healthy lifestyle that
includes exercise and weight reduction. These recommendations were incorporated
into an algorithm to provide pragmatic guidance for clinicians. Conclusion: The
three alternative insulin regimens offer different beneﬁts and drawbacks and it is
important to make the right choice to optimise outcomes for patients.
What’s known
• Treatment of type 2 diabetes aims to maintain
glycaemic control as beta cell function declines
by escalating drug treatment from monotherapy
(usually with metformin) to combined treatment
(usually with a sulfonylurea).
• Many patients ultimately require insulin. NICE
recommends NPH (isophane) insulin as the insulin
of ﬁrst choice, although in practice many
clinicians prescribe a long-acting insulin
analogue.
• There is no guidance on choosing a second-line
regimen when initial therapy fails.
What’s new
• There are three alternative regimens for second-
line insulin therapy: twice-daily premixed; basal-
bolus (once-daily injection of a long-acting insulin
plus injections of a short-acting preparation at
every meal) and basal-plus (basal insulin plus one
or two meal-time injections).
• The choice of regimen should be tailored to
patient need, as reﬂected by six factors
(preference for injection frequency and self-
monitoring blood glucose, variability of lifestyle,
presence of postprandial hyperglycaemia,
patient’s capability and access to support).
• An algorithm has been developed to help
clinicians choose an appropriate insulin regimen.
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insulin with NPH (isophane) insulin or a long-acting
analogue to provide a basal insulin supply (basal
insulin) and includes advice on the choice of initial
insulin. A summary of the different types of insulin
is presented in Box 1.
Glycaemic control with the initial insulin regimen
is suboptimal for the majority of patients: 6 months
after starting insulin, HbA1C is still 7.5% or higher in
74% of patients (2) and after 1 year below 6.5% in
24% or fewer (5). NICE states that, if target HbA1C
with the initial regimen is not reached without prob-
lematic hypoglycaemia, patients using a basal regi-
men should consider additional meal-time doses or
switching to a premixed insulin. For those already
using a premixed insulin once or twice daily, it sug-
gests they should consider an additional meal-time
injection or change to a basal regimen plus meal-
time injections. A regimen comprising once-daily
basal long-acting insulin plus meal-time injections of
a short-acting insulin is known as a basal-bolus regi-
men. The panel used the term ‘basal-plus’ to describe
a regimen comprising a once-daily basal insulin plus
one or two meal-time injections of a short-acting
insulin.
There is currently no guidance on how to imple-
ment this step in insulin treatment in a way that is
tailored to the needs of individual patients. This
reﬂects a lack of randomised trials from which to
develop an evidence-based strategy. In May 2008, an
expert panel (comprising the authors) met to review
current clinical practice with the aim of developing
pragmatic advice that is easy to use during a consul-
tation and will help general practitioners (GPs) tailor
treatment to the needs of individual patients.
Target HbA1C
Good glycaemic control reduces the risk of cardiovas-
cular and microvascular complications but HbA1C
levels within the normal range may be achieved only
with very intensive treatment that carries an unac-
ceptable risk of adverse effects for many people.
Among patients who achieve a target HbA1C of
£ 6.5%, almost half using biphasic insulin and over
one-ﬁfth of those using basal insulin experience
hypoglycaemic events that are symptomatic or
require assistance (5). There is concern that treatment
with basal insulin plus a sulfonylurea may also be
associated with an increased risk of hypoglycaemia.
Patients should therefore be involved in deciding
which HbA1C level is the most appropriate target for
them. Although a target of 6.5% is generally recom-
mended, the beneﬁts of a low HbA1C must be bal-
anced against the risk of hypoglycaemia and weight
gain and the potential impact of treatment on quality
Box 1 Summary of types of insulins
Type of insulin Summary of properties Examples (not exhaustive)
Short-acting insulins Rapid onset but short duration of action suitable for injection
before meals; analogues (insulin aspart, insulin glulisine, insulin lispro)
have faster onset and shorter duration than soluble insulin
Analogues
Apidra
Humalog
NovoRapid
Soluble human insulin
Actrapid
Humulin S
Insuman Rapid
Premixed insulins
(biphasic insulins)
Combination of insulins with complementary durations of
action – e.g. a short-acting (soluble insulin, insulin aspart,
insulin lispro) plus an intermediate-acting insulin
(aspart or lispro protamine insulin, protamine insulin)
Humalog Mix25, Mix50
Humulin M3
Insuman Comb 15, 25, 50
Mixtard30
NovoMix30
Basal and NPH insulins Basal insulins have a prolonged duration of action for once
or twice daily injection (insulin detemir, insulin glargine,
insulin zinc suspension, protamine zinc suspension)
Hypurin Bovine Lente,
Hypurin Bovine Protamine Zinc
Lantus
Levemir
NPH insulins are a complex of bovine or porcine insulin,
or human insulin, with protamine; intermediate duration of action
Humulin I
Insulatard
Insuman basal
NPH, isophane insulin.
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target below 6.5% should be avoided but any move-
ment towards this target is beneﬁcial (4).
The Quality Outcomes Framework (6) speciﬁes an
HbA1C target of between 6.5% and 7.5%. The thresh-
old for the purposes of auditing performance is 7.4%
or less; this is not optimal clinical practice.
The Expert Panel recommends a target HbA1C of
< 7% if this can be achieved in clinical practice, with
a further reduction to 6.5–6.9% if this can be done
safely particularly from the point of view of hypo-
glycaemia.
Relationship of fasting and prandial
hyperglycaemia to HbA1C
Fasting and postprandial blood glucose levels both
contribute to the hyperglycaemia burden in patients
with diabetes but their relative importance depends
on the degree of glycaemic control (7). When control
is good (HbA1C < 7.3%), postprandial hyperglyca-
emia accounts for about 70% of overall diurnal
hyperglycaemia. By contrast, when control is poor
(HbA1C > 10.2%), it is basal hyperglycaemia that
accounts for 70% of the total (Figure 1) (7).
A once-daily long-acting basal insulin controls basal
hyperglycaemia more effectively than meal-time injec-
tions of short-acting insulin; conversely, it controls
postprandial glucose levels less effectively (8). As initial
therapy with a basal insulin reduces HbA1C towards
target, this gain is likely to owe more to improved fast-
ing glucose levels than a reduction of postprandial
hyperglycaemia. While it should be acknowledged that
everyone is different with respect to the balance of
basal and postprandial hyperglycaemia, further
movement towards target HbA1C may subsequently be
best achieved by adding meal-time insulin injections.
Weight gain
Some patients may refuse insulin because of fear of
or actual weight gain. Successful glycaemic control
with insulin is associated with weight gain, although
some patients gain more weight than others and it is
less marked with once-daily basal than twice-daily or
prandial insulin regimens (5). The risk of weight gain
is not equal for all basal insulins; for example, once-
daily insulin detemir is associated with less weight
gain than insulin glargine (9). Intensive lifestyle
intervention during the ﬁrst 6–12 months of insulin
therapy can prevent weight gain (10). Treatments
other than insulin (e.g. exenatide) should be consid-
ered for patients who are obese or who have experi-
enced marked weight gain with the initial insulin
regimen (4). Some patients who need to continue
insulin may require drug treatment to assist weight
loss. Discontinuation of a sulfonylurea should also
be considered in patients with marked weight gain.
Patient education should continue to emphasise the
importance of controlling weight by adopting a
healthy lifestyle and diet.
A pragmatic algorithm for choosing a
second-line insulin regimen
Figure 2 is an algorithm based on a consensus of
expert opinion to support decision-making when ini-
tial insulin therapy fails to achieve target HbA1C or
hypoglycaemic events are a signiﬁcant problem. The
second-line regimen should be chosen according to
individual patient need.
Table 1 lists the factors believed to be most impor-
tant in this decision and indicates which regimens
are preferred for each.
Optimising current therapy
Patients will normally have received lifestyle advice
and education about diabetes and the use of insulin;
this should include discussion of self-monitoring
blood glucose. Subject to contraindications and toler-
ability, they may be taking metformin and⁄or a sul-
fonylurea. The dose of metformin can be limited by
Figure 1 Relative contributions of postprandial and basal
hyperglycaemia to overall diurnal hyperglycaemia at
different quintiles of HbA1C (7). , postprandial
hyperglycaemia; , fasting hyperglycaemia; a, signiﬁcant
difference, fasting vs. postprandial; b, signiﬁcant difference
from all other quintiles; c, signiﬁcant difference from
quintile 5 ‘‘Copyright ª 2003 American Diabetes
Association From Diabetes Care
 , Vol. 26, 2003; 881–885
Reprinted with permission from The American Diabetes
Association.’’
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with initial insulin regimen +/–    oral agents
Switch to basal insulin analogue if using NPH insulin
Optimise lifestyle, education
Ensure taking metformin unless contraindicated/not tolerated
Consider individual needs and preferences (see Table 2)
Twice-daily 
premix
Basal-bolus
(basal dose plus 
3–          5 injections)
Basal dose plus 
1  – 3 meal time 
injections
HbA1C > 7% or hypoglycaemia
HbA1C > 7% or 
hypoglycaemia
Three times 
daily premix
HbA1C > 7% or 
hypoglycaemia
HbA1C > 7% or 
hypoglycaemia
Ensure 
lifestyle
 is 
optimised 
and 
appropriate 
education 
is 
provided 
at 
every 
stage 
before 
altering 
therapy
not common practice
Figure 2 Pragmatic algorithm for choosing second-line insulin therapy in type 2 diabetes
Table 1 Second-line insulin choices for type 2 diabetes: patient factors
Basal-bolus Premix Basal + mealtime injections
Patient preference for fewest injections + +
Variable meal pattern + +
Variable daily routine +
Limited capability (e.g. dexterity, cognitive function) +
Better postprandial glucose control required + +
Unwilling to self-monitor blood glucose several times daily +
Limited support from family and GP + +
+ = preferred choice; GP, general practitioner. The preferred insulin regimen for individual patients is not the one with the most ‘+’
but one which best meets speciﬁc needs.
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preparation may overcome this problem.
Education
Education about healthy diet and weight loss may
improve glycaemic control without the need to alter
drug therapy (11) and should be reinforced every
time treatment is reviewed. If necessary this should
be in addition to annual structured group pro-
grammes. Education should be provided in a way
that is sensitive to the individual’s needs, culture and
beliefs and can be provided by telephone or in face-
to-face meetings. The panel recommends a minimum
of four contacts with the patient in the ﬁrst
6–8 weeks after prescribing second-line insulin ther-
apy.
Diet and lifestyle
Dietary advice should similarly be appropriate to
individual need and encourage the use of high-ﬁbre,
low-glycaemic index carbohydrates, low fat foods
and control of trans and saturated fatty acids intake.
Recommendations for the content and timing of
meals should be individualised. Lifestyle change
should include increased physical activity and weight
loss initially of 5–10% for people who are over-
weight.
Initial insulin regimen
NICE recommends NPH insulin as the insulin of
ﬁrst choice for most patients (4). However, at a simi-
lar level of glycaemic control, a long-acting insulin
analogue is associated with a lower risk of hypoglyca-
emia than NPH insulin in patients taking metformin
(12) and patients may prefer the convenience of a
once-daily basal regimen. When target HbA1C cannot
be met without an increased risk of hypoglycaemia,
or hypoglycaemic events become troublesome as the
target is approached, switching to a long-acting ana-
logue may improve the balance of beneﬁt and risk.
Patients should be warned of the possibility that
hypoglycaemic episodes may increase during adjust-
ment of insulin therapy and that this will affect their
ability to drive. Information about the requirements
for driving are summarised by the DVLA in At a
Glance; copies are available at http://www.dvla.
gov.uk/media/pdf/medical/aagv1.pdf.
Options for second-line insulin regimens
When treatment, including lifestyle and oral hypogly-
caemic drugs, has been optimised but glycaemic con-
trol is still unsatisfactory, the options for second-line
insulin therapy are:
• Substituting a twice-daily premixed insulin,
increasing to three times daily if required. When
switching from a basal regimen to a twice-daily
injections of premixed insulins, the initial dose
should be 80% of the ﬁnal basal dose; this should
then be titrated to target over 2 weeks.
OR
• Basal plus meal-time injections with a short-acting
insulin analogue, beginning with one additional
injection per day (determined by highest postpran-
dial reading from blood glucose monitoring), and
increasing injection frequency according to need
(basal-plus); meal-time doses are adjusted according
to blood glucose measurement. This regimen is not
common clinical practice.
OR
• A full basal-bolus regimen (a basal dose plus injec-
tions of a short-acting insulin analogue with every
meal); meal-time doses are calculated according to
blood glucose measurement.
The Expert Panel did not make recommendations
for choosing speciﬁc insulins. Clinical experience
shows that the preferences and capabilities of
patients and the support available to them are the
main determinants for choosing a second-line insulin
regimen (Table 1). These options should be discussed
with the patient, who should participate fully in the
decision to agree a regimen. GPs and practice nurses
should consider requesting specialist help at any
stage.
Practical issues
Injection frequency
Many patients dislike frequent insulin injections (13)
and self-monitoring blood glucose, which many
clinicians recommend for such intensive insulin
therapy, is associated with increased scores of depres-
sion and lower quality of life scores (14,15). A basal-
bolus regimen requires multiple daily injections
(4–6⁄day). Premixed insulins (2 injections⁄day)
provide superior meal-time cover compared with
the basal-plus regimen (2–4 injections⁄day). The
basal-plus regimen also offers a transition phase for
patients who are ultimately likely to use basal-bolus
therapy.
Variable meal pattern and daily routine
Insulin requirement can be more closely matched to
insulin dose by administering multiple injections of a
short-acting insulin in addition to a basal dose. The
duration of action of premixed insulins is too long
to provide such ﬂexibility and the ratios of the com-
ponent short- and long-acting insulins cannot be
adjusted to meet variable demand. These formula-
tions carry an increased risk of hypoglycaemia if
meal patterns and physical activity are not consistent.
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better suited to a premixed regimen.
Patient’s capability
Patients who are unable to cope well with their injec-
tions, either because of the practical obstacles to han-
dling the pen or difﬁculty understanding the process
of monitoring and dose adjustment, should minimise
the number of doses they need, reduce the need for
frequent blood glucose monitoring and use a ﬁxed-
dose regimen.
Postprandial hyperglycaemia
Meal-time doses of a short-acting insulin are indi-
cated if postprandial hyperglycaemia is believed to be
a particular problem. The target for postprandial glu-
cose levels is £ 7.8 mmol⁄l; patients should be
encouraged to self-monitor blood glucose to help
them reach this target (16).
Self-monitoring blood glucose
Meal-time doses in basal-plus and basal-bolus regi-
mens are adjusted according to blood glucose mea-
surements, meaning multiple daily ﬁnger pricks in
addition to the injections themselves. Such careful
tailoring of the insulin dose comes at a price for
patients with type 2 diabetes, who report increased
scores of depression and lower quality of life scores
(13,14). A premixed regimen may then be preferred.
Availability of support
More education and training is needed to introduce
a basal-bolus regimen than other regimens and this
has implications for practice resources. Ideally, basal-
bolus regimens should only be prescribed by prac-
tices that can provide adequate support and training
for their staff.
Patients who can be helped to manage their injec-
tions by a carer or nurse have a greater choice of
insulin regimens. However, it is important that injec-
tions should be administered at the time the patient
needs them rather than to accommodate the carer’s
work schedule. Given the additional workload associ-
ated with a basal-bolus regimen, there may be a need
to minimise injection frequency for individuals who
do not have sufﬁcient support.
Summary
Type 2 diabetes is a progressive disorder associated
with declining pancreatic beta cell function and
increasing insulin resistance. Most patients eventually
require insulin to maintain glycaemic control.
Guidance has been published on the choice of the
initial insulin regimen but not on how to choose a
second regimen when glycaemic control becomes
unsatisfactory. The three options – premixed insu-
lins, basal-plus and basal-bolus regimens – offer dif-
ferent beneﬁts and drawbacks and it is important to
make the right choice to optimise outcomes for
patients.
This pragmatic guidance aims to help GPs choose
the second-line insulin regimen that best meets the
needs of individual patients. Taking into account
patient preferences, lifestyle and functional capacity,
it identiﬁes which are the most suitable alternatives.
However, it recognises the importance of emphasis-
ing the beneﬁts of a healthy lifestyle that includes
exercise and weight reduction.
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